- Home
- PB vs STVN Comparison
PB vs STVN Comparison
Compare PB & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PB
- STVN
- Stock Information
- Founded
- PB 1983
- STVN 1949
- Country
- PB United States
- STVN Italy
- Employees
- PB N/A
- STVN N/A
- Industry
- PB Major Banks
- STVN Containers/Packaging
- Sector
- PB Finance
- STVN Consumer Discretionary
- Exchange
- PB Nasdaq
- STVN Nasdaq
- Market Cap
- PB 6.1B
- STVN 5.7B
- IPO Year
- PB 1998
- STVN 2021
- Fundamental
- Price
- PB $71.29
- STVN $24.05
- Analyst Decision
- PB Buy
- STVN Buy
- Analyst Count
- PB 15
- STVN 6
- Target Price
- PB $84.00
- STVN $25.08
- AVG Volume (30 Days)
- PB 755.5K
- STVN 305.4K
- Earning Date
- PB 04-23-2025
- STVN 05-08-2025
- Dividend Yield
- PB 3.26%
- STVN 0.25%
- EPS Growth
- PB 20.96
- STVN N/A
- EPS
- PB 5.23
- STVN 0.50
- Revenue
- PB $1,212,807,000.00
- STVN $1,215,559,879.00
- Revenue This Year
- PB $12.40
- STVN $8.42
- Revenue Next Year
- PB $7.82
- STVN $10.36
- P/E Ratio
- PB $13.61
- STVN $47.26
- Revenue Growth
- PB 11.62
- STVN 3.81
- 52 Week Low
- PB $57.16
- STVN $16.56
- 52 Week High
- PB $86.76
- STVN $28.77
- Technical
- Relative Strength Index (RSI)
- PB 61.88
- STVN 66.95
- Support Level
- PB $68.80
- STVN $20.14
- Resistance Level
- PB $71.53
- STVN $22.61
- Average True Range (ATR)
- PB 1.42
- STVN 1.10
- MACD
- PB 0.63
- STVN 0.18
- Stochastic Oscillator
- PB 95.85
- STVN 95.45
About PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.